Please login to the form below

Not currently logged in
Email:
Password:

Zerbaxa

This page shows the latest Zerbaxa news and features for those working in and with pharma, biotech and healthcare.

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

In the cross-hairs is MSD’s Centre de Mirabel site in Riom, which specialises in the manufacture and packaging of sterile drugs like injectable antibiotic Zerbaxa (ceftolozane/tazobactam) and ophthalmic

Latest news

  • Merck defeated in antibiotic patent case in US Merck defeated in antibiotic patent case in US

    In addition to Cubicin, buying Cubist has also given Merck Sivextro (tedizolid phosphate) - anther treatment for skin and skin structure infections, and Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal and urinary ... Neither of these

  • Merck prepares filings for Clostridium antibody Merck prepares filings for Clostridium antibody

    Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

  • Shire and Baxalta drugs among CHMP's latest recommendations Shire and Baxalta drugs among CHMP's latest recommendations

    Merck Sharp &Dohme's Zerbaxa (ceftolozane / tazobactam) for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections.

  • Relief as study finds no cardiovascular risk with Januvia Relief as study finds no cardiovascular risk with Januvia

    Meanwhile, first-in-class insomnia therapy Belsomra (suvorexant) and new antibiotic Zerbaxa (ceftolozane/tazobactam) also got off to a good start, according to chief executive Kenneth Frazier.

  • Actavis gets FDA nod for new antibiotic Actavis gets FDA nod for new antibiotic

    Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2014 Pharma deals during December 2014

    Buoyed with the news in mid-December of the FDA approval of another Cubist antibiotic, Zerbaxa (ceftolozane/tazobactam), for the treatment of various Gram-negative bacterial infections, it looks as if

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics